It is made available under a CC-BY 4.0 International license .

# 1 The neurodevelopmental spectrum of *CASK*-related disorder

- 2 Jessica Martin<sup>1</sup>, Alkistis Mavrogalou-Foti<sup>1</sup>, Josefine Eck<sup>1</sup>, Laura Hattersley<sup>2</sup>, Kate Baker<sup>1, 3, 4</sup>
- 3 <sup>1</sup> MRC Cognition and Brain Sciences Unit, University of Cambridge
- 4 <sup>2</sup> CASK Research Foundation
- 5 <sup>3</sup> Department of Medical Genetics, University of Cambridge
- <sup>6</sup> <sup>4</sup> Department of Pathology, University of Cambridge
- 7 \*Correspondence to Kate Baker: <u>kate.baker@mrc-cbu.cam.ac.uk</u>

It is made available under a CC-BY 4.0 International license .

## 8 Abstract

9 Background: Pathogenic CASK variants are associated with neurodevelopmental disorders of 10 variable severity including X-linked intellectual disability (XLID) and microcephaly with 11 pontocerebellar hypoplasia (MICPCH). Although the number of diagnosed cases is rising, current 12 understanding of the CASK-related neurodevelopmental spectrum is limited. Here, we systematically 13 review the published characteristics of individuals with CASK-related disorder, and compare these to 14 a more recently-diagnosed group. We provide quantitative information about the ranges of adaptive 15 abilities, motor function, visual function and social-emotional-behavioural characteristics, and 16 explore within-group associations.

Methods: 151 individuals with *CASK* variants were identified in published literature. 31 children and young people with *CASK* variants were recruited to the UK-based Brain and Behaviour in Neurodevelopmental disorder of Genetic Origin (BINGO) project. BINGO-participating caregivers completed a bespoke medical history questionnaire and battery of standardised neurodevelopmental measures.

22 Results: Comparing the recently diagnosed BINGO CASK-related disorder group to previously 23 reported individuals, we found consistent prevalence of tone abnormalities, sensorineural hearing 24 loss and epilepsy, but lower prevalence of severe/profound ID, MICPCH, optic atrophy and 25 nystagmus. Areas of frequent difficulty not highlighted in previous reports include sleep difficulties 26 and cerebral visual impairment (CVI). Neurodevelopmental characteristics were highly variable 27 within the BINGO CASK-related disorder group, and group-wide patterns were similar to those 28 observed in other rare genetic conditions. Within the BINGO CASK-related group, epilepsy is 29 significantly associated with ID severity, after controlling for age. Sub-groups with MICPCH or 30 microcephaly only have equivalent ranges of adaptive function, but MICPCH may be associated with 31 more severe motor difficulties.

It is made available under a CC-BY 4.0 International license .

- 32 Conclusion: The spectrum of neurodevelopmental characteristics associated with CASK-related
- 33 disorder appears to be broadening with increased access to genome-wide diagnostic testing.
- 34 Further studies are needed to elucidate the relationships between CASK variants, structural brain
- 35 development, epilepsy, and neurodevelopmental characteristics.

# 36 Keywords

- 37 CASK-related disorder, X-linked Intellectual Disability, MICPCH, Epilepsy, Autism characteristics,
- 38 Adaptive function, Cerebral Visual Impairment, Genetic, Sleep difficulties

It is made available under a CC-BY 4.0 International license .

## 39 Background

40 Calcium/calmodium-dependent serine protein kinase (CASK) is a multi-domain scaffolding protein 41 and a member of the membrane-associated guanylate kinase (MAGUK) family, with diverse neuronal 42 functions (reviewed in 1). Several neurodevelopmental presentations have been reported in 43 association with CASK variants including: X-linked intellectual disability (XLID) (2,3), microcephaly 44 with pontine and cerebellar hypoplasia (MICPCH) (4–6), XLID with or without nystagmus and 45 microcephaly (7,8), X-linked optic and ophthalmic problems (9), and FG syndrome (10,11). Prior to 46 next generation sequencing (NGS) diagnostics, most individuals with CASK-related diagnoses were 47 identified phenotype-first based on these descriptions. With the application of genotype-first NGS 48 diagnostic approaches and broader ascertainment of individuals with neurodevelopmental 49 presentations for clinical genetic testing, the number of individuals diagnosed with a CASK-related 50 disorder is rising. Consequently, the reported CASK-associated phenotypic spectrum may not be fully 51 representative. There is an urgent need for an up-to-date phenotypic evidence base which can 52 contribute to variant interpretation and provide accurate information about the nature and range of 53 long-term challenges faced by this patient group.

In particular, there has been limited characterisation of cognitive, adaptive, behavioural and socialemotional functions within *CASK*-related disorder. Almost all reported individuals have developmental delay and intellectual disability (ID) (12), and there have been several reported cases of autism spectrum disorder (ASD) and autism-related traits (13–16). However, no systematic evaluation of neurodevelopmental domains has been published. Standardised measures of motor function, communication and social-emotional functions appropriate for individuals with ID have not been included within any case series.

Additionally, the factors predicting neurodevelopmental variation within *CASK*-related disorder are unclear. Truncating and missense variants have been associated with more severe and less severe presentations respectively, with males being more severely affected than females within either

It is made available under a CC-BY 4.0 International license .

64 variant group (12). However, there are exceptions to this pattern, such as a nonsense variant 65 identified in a mildly affected male patient (14) and missense variants identified in severely affected 66 females (17,18). Moreover, gender and variant type cannot enable precise predictions of ID severity, 67 because the majority of CASK-diagnosed individuals are female and have truncating variants. Beyond 68 genotype, the presence and extent of neuroanatomical abnormalities could be another predictor of 69 neurodevelopmental variation. For example, a relationship has been observed between more severe 70 MRI findings (i.e., MICPCH) and a more severe clinical presentation (i.e., epilepsy, ophthalmologic, 71 motor and speech problems), in males but not females with CASK variants (19,20). Another potential 72 within-group influence on neurodevelopment could be epilepsy, which affects around 50% of 73 individuals with a CASK variant (21,22), and can predict developmental abilities in other monogenic 74 conditions (23–26). One preliminary study in CASK-associated disorder did not find evidence for a 75 link between epilepsy characteristics and severity of developmental delay (21), but variant type and 76 gender may be confounding factors.

77 In this paper, we aim to address these gaps and provide a comprehensive phenotypic description of 78 CASK-related disorder. First, we present a structured review of published clinical case series, to 79 provide a benchmark for comparison to 31 individuals with CASK variants assessed via a structured 80 parent-report questionnaire within a wider research study (BINGO – Brain and Behaviour in 81 Neurodevelopmental disorders of Genetic Origin). This comparison enables us to establish whether 82 the CASK-related phenotypic spectrum is changing in parallel with broader ascertainment and 83 genotype-first diagnostics. Second, we present standardised multi-domain neurodevelopmental data 84 for the BINGO CASK participant group, to document their range of abilities and difficulties, including 85 relationships between domains. Third, we explore whether neurodevelopmental variation within 86 this group is associated with neuroanatomical abnormalities or epilepsy.

## 87 Methods

#### 88 Literature Review

It is made available under a CC-BY 4.0 International license .

89 We conducted a review of literature describing the clinical features of individuals with CASK-related 90 disorder. Relevant literature published up until May 2024 was identified on Medline (PubMed) and 91 Google Scholar using the search terms "CASK", "CASK-related disorders", "microcephaly", "MICPCH", 92 and "pontocerebellar hypoplasia". Additional papers were identified from bibliographies. We 93 included case series that reported (A) at least three individuals with CASK-related disorder who had 94 not been previously described and (B) clinical characteristics assessed via direct evaluation or 95 retrospective review of available medical records. Using these inclusion criteria, we identified 15 96 papers. We excluded Hayashi et al. (2012)(4) from the review as all individuals were later described 97 in Takanashi et al., (2012)(27). Individuals previously described in Valayannopoulos et al., (2012)(28) 98 and Takanashi et al., (2012)(27) were also excluded from our summary of Burglen et al., (2012)(19) 99 and Hayashi et al., (2017)(5), respectively. Thus, our review includes 14 papers and, to the best of 100 our knowledge, summarises unique individuals with CASK-related disorder.

#### 101 BINGO data collection

#### 102 Participants

103 Children and young people (CYPs) with CASK-related disorder were recruited to BINGO via an 104 international network of CASK-related charities (CASK Research Foundation, Angelina CASK 105 Neurological Research Foundation, Association Enfants CASK France), UK-based charities for rare 106 conditions (Unique, Cambridge Rare Disease Network, Genetic Alliance UK), and regional genetic 107 services in the UK. CYPs were eligible if they were aged at least 3 years old, experienced 108 neurodevelopmental difficulties, and had a pathogenic or likely pathogenic CASK gene variant, or a 109 variant of uncertain significance, which was previously fed-back via a clinical genetic services as likely 110 related to clinical presentation. Genetic diagnoses were confirmed via medical records. CASK 111 variants were classified as single nucleotide variants (SNVs) or copy number variants (CNVs). SNVs 112 were annotated as either (a) protein-truncating, (b) intronic or (c) missense variants; CNVs were

It is made available under a CC-BY 4.0 International license .

annotated as either (a) intragenic or (b) multi-gene in line with previous literature on pathogenic

114 CASK genotypes.

#### 115 Phenotyping methods

Parent-report questionnaires were completed online, by post, or via Zoom or telephone interview according to parent preference. Clinical information was gathered via a study-specific medical history questionnaire (MHQ) covering prenatal, infancy and childhood health, plus acquisition of developmental milestones. Information regarding structural brain abnormalities was obtained via Magnetic Resonance Imaging reports (MRI; n = 14), genetic test reports (n = 9) and parental reports (n = 2). Standardised neurodevelopmental questionnaires and procedures for scoring and analysis are described in Supplementary Table 1.

#### 123 Statistical analysis

124 BINGO data were analysed using R studio, version 2023.3.0.386. Where participants had partial 125 datasets, all available data were included in analyses. Raincloud plots were generated for each 126 questionnaire measure. Cut-off scores were overlaid on each raincloud plot where possible to 127 contextualise the severity of difficulties in CASK-related disorder relative to normative populations, 128 or previously reported literature. Within-sample relationships were explored between demographic 129 (age, sex), neurological (epilepsy), developmental (Vinland Adaptive Behaviour Scales (VABS; 29) 130 composite score, Flemish Cerebral Visual Impairment Questionnaire (FCVIQ; 30) total score, and 131 social-emotional-behavioural (total scores on the Social Responsiveness Scale (SRS-2; 31), the 132 Developmental Behaviour Checklist (DBC2; 32), and the Repetitive Behaviour Questionnaire (RBQ; 133 33)) characteristics using statistical tests appropriate to data type. Non-parametric methods were 134 selected if data violated the assumption of normality, and Kendall's tau correlation was chosen over 135 Spearman's rank correlation if ties represented more than 20% of the data. To reduce the likelihood 136 of type I errors, p-values were adjusted for multiple testing by applying a Benjamini-Hochberg False 137 Discovery Rate (B-H FDR) correction. Regression analyses were used to examine the influence of

It is made available under a CC-BY 4.0 International license .

epilepsy on adaptive function (VABS composite score). The assumptions of regression were tested prior to analyses (Supplementary Table 6a and 7a). Descriptive differences were explored between CYPs with different neuroanatomical abnormalities (MICPCH vs. microcephaly only vs. no abnormalities reported). Variables explored were demographic characteristics, VABS composite scores and VABS motor domain scores, FCVIQ total scores and epilepsy prevalence.

143 **Results** 

### 144 Review of published cases

Supplementary Table 2 summarises the clinical characteristics of 151 individuals carrying *CASK* variants, reported in previous publications. The majority were female (72.2%) and age ranged from 2 weeks to 49 years old at the time of reporting. SNVs accounted for 71.5% of *CASK* variants, encompassing protein-truncating (44.4%), intronic (35.2%), and missense (20.4%) variants. CNVs (28.5%) included both intragenic (48.8%) and multi-gene (51.2%) deletions of varying sizes. De novo variants (77.3%) were more common than inherited variants (22.7%).

151 The most frequently reported clinical problems were feeding difficulties (57.1%), including 152 gastroesophageal reflux, sucking and swallowing difficulties. Interventions such as thickened 153 liquids/pureed foods, nasogastric tube or gastrostomy were common, although feeding difficulties 154 were noted to improve with age in some individuals (1,20). Tone abnormalities were also frequent, 155 including hypotonia (57.1%), hypertonia (41.8%) or mixed tone abnormalities (14%). Epilepsy was 156 reported in 48.9% overall. Seizure details were inconsistently reported, but a range of seizure types 157 were described, including early infantile epileptic encephalopathies with variable EEG phenotypes 158 (e.g., West Syndrome, Ohtahara syndrome), infantile spasms, later-onset epilepsies (generalised or 159 focal) and myoclonic epilepsies. Many individuals had mixed seizure types and there was a variable 160 response to anti-seizure medications from remission to intractable. Optic atrophy (28.6%), 161 strabismus (30.4%) and nystagmus (25%) were common ophthalmological abnormalities co-

It is made available under a CC-BY 4.0 International license .

occurring with each other. Other reported vision-related phenotypes included astigmatism, myopia,
hyperopia, retinopathy, glaucoma and cerebral visual impairment (CVI). Sensorineural hearing loss
was present in 24.6%. Other characteristics less frequently reported were scoliosis, kidney problems
and sleep disturbances.

166 The majority of reported individuals with CASK-related disorder had severe or profound 167 developmental delay (88%). 56.6% were able to sit without support and acquired this ability 168 between 6 months and 3 years. Fewer individuals (25.7%) had acquired the ability to walk 169 independently with age of acquisition ranging from 18 months to 6 years. There were also three 170 reports of regression of motor abilities, including a case of mild regression at 2 years (6), an 171 individual that lost ability to walk at 25 years after severe febrile seizures (1), and an individual that 172 lost ability to sit after scoliosis surgery (14). A minority of individuals were reported to use some 173 vocal communication (33.8%), which ranged from babbling and vocalisations to short sentences. 174 Two papers reported individuals using Augmentative and Alternative Communication (AAC) systems 175 as non-verbal methods of communication, such as an eye gaze device and Picture Exchange 176 Communication System (PECS; 14,19).

177 In the papers we identified, there was a limited focus on social, emotional and behavioural problems 178 with only four papers describing social or emotional-behavioural difficulties, such as ASD (1,14), self-179 injurious behaviours (19) and general behavioural difficulties (28).

Where MRI data were reported, the majority of individuals with *CASK* variants had MICPCH (87.1%). There were also five individuals with cerebellar and/or pontine hypoplasia only (3.6%), four individuals with microcephaly and other brain abnormalities (2.9%), three cases of microcephaly with cerebellar hypoplasia only (2.1%), three of microcephaly only (2.1%), and three reports of no brain abnormalities (2.1%).

185 Comparison between reviewed cases and BINGO CASK-related group

It is made available under a CC-BY 4.0 International license .

186 Thirty-one CYPs with CASK-related disorder participated in BINGO and were included in this analysis. 187 Comparison between demographic and clinical characteristics of BINGO participants and the 188 reviewed population is summarised in Table 1. A higher proportion of the BINGO group were female, 189 and the age range was narrower due to an age limit for BINGO eligibility. The proportion of 190 individuals with either CASK SNVs or CNVs were near identical between reviewed cases and BINGO, 191 although the BINGO group contained a higher proportion of truncating SNVs versus missense SNVs, 192 and higher proportion of intragenic versus multi-gene CNVs. There were fewer reports of MICPCH in 193 the BINGO group (44.0% vs. 87.1%) and more reports of microcephaly only (32.0% vs. 2.1%).

194 A higher percentage of feeding difficulties was reported in BINGO (83.9% vs. 57.1%), but the range of 195 difficulties and interventions reported were similar to the reviewed group. The frequency of 196 reported tone abnormalities, sensorineural hearing loss and epilepsy were comparable between the 197 BINGO group and reviewed group. A range of seizure types were reported in BINGO, including 198 infantile spasms, myoclonic epilepsies, as well as focal, complex and absence seizures. The age of 199 seizure onset varied from 4 months to 10 years. Reports of strabismus, refractive errors and CVI 200 were similar between BINGO and reviewed cases, but optic atrophy and nystagmus were not 201 common in the BINGO group (9.7% and 3.2%, respectively) compared to reviewed cases (28.6% and 202 25%, respectively). Sleep difficulties were common in our sample (74.12% ever experienced) but 203 were not widely reported in previous literature (see 19 for exception). Parents reported a range of 204 sleep-associated problems including difficulty settling, regular waking, and need for more or less 205 sleep than expected for age, as well as sleep apnoea.

There were notable differences between BINGO and the reviewed group in acquisition of developmental milestones, whereby a higher percentage of the BINGO group had acquired the ability to sit (87.1% vs. 56.6%) and walk (51.6% vs. 25.7%). Reported verbal abilities were similar across the two groups. Categorisation of ID severity also differed between groups, with a higher percentage of the BINGO group in the mild or moderate (60.7% vs. 12.0%) rather than severe (25.0%

It is made available under a CC-BY 4.0 International license .

#### 211 vs. 75.0%) category, noting that this categorisation was based on VABS data in BINGO but clinical

- 212 report in the reviewed sample.
- 213 INSERT TABLE 1

### 214 Neurodevelopmental variation within the BINGO CASK-related group

Figures 1-5 show the distribution of scores on neurodevelopmental and social-emotional-

216 behavioural measures. VABS composite scores indicated that global adaptive ability ranged from

217 mildly impaired to severely/profoundly impaired (Figure 1). Communication was the most affected

subdomain, whereas Socialisation was a relative strength.

219

#### INSERT FIGURE 1

220 Scores on the SRS-2 revealed high levels of autism-related traits, varying in severity within the 221 atypical range. CYPs with CASK-related disorder demonstrate relative strengths in social motivation 222 on the SRS-2, compared to other social subscales or Restricted and Repetitive Behaviours (Figure 2). 223 These patterns are overall similar to observations in other rare genetic conditions (34,35). The 224 majority of DBC2 scores were in the moderate-serious concerns range (Figure 3), with relatively 225 greater difficulties with self-absorbed behaviour (a DBC-2 subscale involving diverse items including mouthing objects, special interests and stereotyped behaviours). On the RBQ, the majority of 226 227 participants scored above the threshold for 'normal' levels of repetitive behaviours, and scored 228 relatively higher on the stereotyped subdomain (Figure 4). Challenging Behaviour Questionnaire 229 (CBQ, 36) reported rates of self-injury (42.86%), physical aggression (46.43%) and stereotyped 230 behaviour (50.00%) were high (Supplementary Table 3), but similar to rates observed in other rare 231 neurogenetic conditions (37,38). The severity of these behaviours also varied, but on average was 232 similar to those reported in individuals with other rare neurogenetic conditions (39).

233

#### **INSERT FIGURE 2**

234

**INSERT FIGURE 3** 

It is made available under a CC-BY 4.0 International license .

235

#### **INSERT FIGURE 4**

236 The majority of CYPs with CASK-related disorder are at risk of CVI, according to FCVIQ Sum Scores (M 237 = 5.10, SD = 1.21, range: 2-6; 90% above cut-off score of 4). Factor scores on the FCVIQ show that 238 the BINGO CASK-related group experienced difficulties with object and face processing, visual 239 interest, moving in space and anxiety-related behaviours of a level comparable to children with CVI, 240 whereas clutter and distance viewing might be relatively spared (Figure 5). Broadening to other 241 aspects of sensory development, most participants scored within the 'like the majority of others' 242 range on the Seeking and Avoiding subdomains of the Short Sensory Profile (SSP-2; 40) 243 (Supplementary Table 4), but within the 'more than others' and the 'much more than others' range 244 on the Sensitivity and Registration subdomains, respectively. The majority of participants also scored 245 within the 'more than others' and the 'much more than others' ranges on the sensory and 246 behavioural section of the SSP-2, indicating that CYPs with CASK-related disorder display more 247 sensory-related behaviours than most children.

248

#### INSERT FIGURE 5

### 249 Associations within the BINGO CASK-related group

Figure 6 and Supplemental Table 5 show the statistical relationships between demographic, neurological, developmental and social-emotional-behavioural characteristics within *CASK*-related disorder. We found moderate positive correlations between reversed VABS composite scores and (1) age ( $r_s = 0.78$ , p.adj < .01), and (2) epilepsy ( $r_{pb} = 0.55$ , p.adj = .03). We also found a moderate positive correlation between total scores on the DBC2 and RBQ ( $\tau = 0.55$ , p.adj < .01). No other relationship survived the B-H FDR correction for multiple testing.

256

#### **INSERT FIGURE 6**

257 When exploring factors that might contribute to neurodevelopmental variation within *CASK*-related 258 disorder, we found epilepsy was a significant predictor of adaptive ability (F(1, 25) = 10.69, p < .001),

It is made available under a CC-BY 4.0 International license .

and explained approximately 27% of the variance in adaptive ability (Supplementary Table 6b). We also examined whether entering age as a predictor into this model would affect the relationship between epilepsy and adaptive ability, as we found age was significantly positively correlated with adaptive ability. The overall model was significant (F(2, 24) = 16.38, p < .001) and explained approximately 54% of the variance in adaptive ability. As shown in Supplementary Table 7b, epilepsy remained a significant independent predictor of adaptive ability ( $\beta = 11.00$ , p = .032) and age was also a significant independent predictor of adaptive ability ( $\beta = 1.56$ , p < .001).

266 In addition to epilepsy, available data facilitated descriptive exploration of whether neuroanatomical 267 abnormalities might contribute to neurodevelopmental variation within CASK-related disorder. For 268 the purposes of this analysis, we combined MRI findings into three categories: MICPCH (i.e., 269 individuals with reported microcephaly and pontocerebellar abnormalities), Microcephaly (i.e., 270 individuals with reported microcephaly but without reported pontocerebellar abnormalities), and 271 Normal (i.e., individuals without reported microcephaly or neuroanatomical abnormalities). 272 Individuals for whom no brain abnormality data were available, were classified as NA. Groups were 273 not large-enough for statistical analysis, however, as shown in Supplementary Table 8, average 274 scores on the VABS composite were similar between individuals with MICPCH (M = 40.15) and 275 microcephaly only (M = 43.62), but average scores on the motor subdomain of the VABS differed, 276 whereby individuals with MICPCH scored lower (M = 30.54) than individuals with microcephaly only 277 (M = 46.88). Parent-reported epilepsy was also more common in individuals with MICPCH (53.85%) 278 than microcephaly only (33.33%). Only two individuals were documented as having no 279 neuroanatomical abnormalities, hence comparison to this group is not warranted.

## 280 Discussion

Previous studies of *CASK*-related disorder are largely based on retrospective medical reports of individuals identified phenotype-first, with few involving real-time assessments of developmental ability or social-emotional-behavioural symptoms. To overcome these knowledge gaps for the

It is made available under a CC-BY 4.0 International license .

current and future population of individuals diagnosed with *CASK*-related disorder, we first carried out a comprehensive review of the published clinical characteristics and compared prevalence rates to a more recently diagnosed group of CYPs with *CASK* variants (> 60% diagnosed after 2015). We then evaluated the range of developmental abilities and social-emotional-behavioural problems within this group, using standardised measures validated for individuals with ID. Lastly, we explored potential predictors of neurodevelopmental variation within *CASK*-related disorder, to identify possible markers of prognosis, or mediators of developmental trajectory.

291 Comparison of the BINGO CASK-related group to previous literature provides preliminary evidence 292 for an expanding CASK-related phenotype. A lower frequency of developmental delay, severe ID, 293 and characteristics previously considered typical for CASK-related disorder (e.g., MICPCH, optic 294 atrophy, nystagmus) were observed in the BINGO group, suggesting the within-group distribution of 295 neurodevelopmental impairments has shifted to include individuals with less severe presentations. 296 These differences could be attributed to sample ascertainment and measurement. CYPs in BINGO 297 were recruited genotype-first, with broad inclusion criteria, reflecting identification of patients in 298 clinical settings i.e. genetic testing for a wide range of developmental concerns, rather than discreet 299 neuroanatomical or ophthalmological diagnoses. Assessment of ID severity varies between medical 300 centres and countries due to differing guidelines and practice. Similarly, accessibility of 301 neuroimaging and reporting of neuroradiological assessments is inconsistent. Adoption of 302 standardised measures, like the VABS in this study, or routine assessment of neuroanatomy could 303 help progress our understanding of CASK-related characteristics across cohorts and time. 304 Nevertheless, the clinical spectrum of CASK-related disorder within BINGO may more closely reflect 305 the currently-diagnosed CASK-related disorder population.

306 We also identified characteristics associated with *CASK*-related disorder not highlighted in previous 307 case series, which may require increased clinical attention. For example, sleeping difficulties, such as 308 regular night waking and difficulty settling, were commonly reported in our sample of CYPs with

It is made available under a CC-BY 4.0 International license .

309	CASK-related disorder, but were not described in previous literature (with the exception of 19).
310	Specific sleep disorders, along with poor sleep quality, timing, and duration, are common in
311	individuals with ID and rare genetic syndromes (41–43), and parents of individuals with rare genetic
312	conditions frequently highlight sleep as a significant area of concern (44,45). Moreover, poor sleep
313	can be associated with poor adaptive abilities (46,47) and increased challenging behaviour (48–50).
314	As such, it is possible that poor sleep might contribute to observed adaptive and social-emotional-
315	behavioural difficulties in CYPs with CASK-related disorder. However, the assessment of sleep
316	difficulties in this study was limited and future studies should strive to generate objective
317	descriptions of sleep difficulties and specific sleep disorders, as well as factors contributing to sleep
318	disturbance such as pain or epilepsy, which are imperative for effective management.
319	We also found that the majority of CYPs with CASK-related disorder were at risk of CVI (according to
320	FCIVQ Sum Scores), however clinical assessments are needed to confirm these findings as only 5
321	participants in this sample had parent-reported CVI. CVI has been commonly reported in other
322	monogenic conditions with similar genotypic or phenotypic characteristics (51,52). There is a strong
323	association between CVI and seizures across monogenic conditions, in particular infantile spasms
324	(52). This may be particularly relevant for CASK, as infantile spasms are the most common seizure
325	type within the group (21).
326	Despite high levels of difficulties across adaptive and social-emotional-behavioural measures, few
~~~	

significant relationships between measures were identified in the BINGO group of CYPs with *CASK*related disorder. In other words, difficulties in one developmental dimension do not necessarily go alongside difficulties in another dimension, and categorisation of individuals with *CASK*-related disorder as being mildly or severely affected overall may be overly simplistic. A lack of association could suggest that different characteristics, for example autism-related traits and CVI, might be unique dimensions of neurodevelopmental variability in *CASK*-related disorder. However, we only examined the relationships between total scores on these measures and it is possible that

It is made available under a CC-BY 4.0 International license .

subdomains of autism-related traits and CVI, or specific adaptive functions and challenging behaviours, might be related. Further analysis of the relationships between dimensions using additional methods, in a larger *CASK*-related group and over time, are necessary to understand potential developmental links.

338 Prognostic markers of developmental ability are of interest to parents and clinicians in order to plan 339 support needs and consider potential interventions. We found that the presence of epilepsy predicts 340 poorer adaptive ability in CASK-related disorder. One possible interpretation is that seizure activity 341 negatively impacts cognitive development in CASK-related disorder, a relationship also observed in 342 other rare genetic conditions (23–26). Alternatively, epilepsy and poorer adaptive ability might both 343 reflect altered trajectories of brain development, but are not causally related to one another. 344 Moreover, anti-seizure medication has been associated with cognitive dysfunction, but evidence of 345 these effects are mixed in part because of heterogeneities within the paediatric epilepsy population 346 (53,54). To better understand the possible effects of epilepsy and its treatments on other aspects of 347 CASK-related disorder, neurological data adopting standardised International League Against 348 Epilepsy classification (55) and quantification of epilepsy severity and medication use plus 349 longitudinal assessment of cognitive functions are required.

350 In contrast, we did not find descriptive differences in global adaptive ability between individuals with 351 MICPCH and microcephaly only. This may suggest that cortical abnormalities, rather than hindbrain 352 abnormalities, contribute to developmental delay and cognition in CASK-related disorder. This is 353 inconsistent with the previous presumption that individuals with MICPCH will be more severely 354 affected (12,20). However, we observed poorer average motor abilities in CYPs with MICPCH than 355 those with microcephaly only, confirming contribution of cerebellar abnormalities to motor 356 development. These findings are observational and MRI data was limited (only available for 50% of 357 the BINGO CASK-related disorder sample). Future studies with comparable MRI data are needed to

It is made available under a CC-BY 4.0 International license .

358 statistically interrogate the relationships between neuroanatomical abnormality and 359 neurodevelopmental dimensions in *CASK*-related disorder.

# 360 Conclusions

- 361 In conclusion, we provide an up-to-date description of the characteristics associated with CASK-
- 362 related disorder, which includes a diverse range of clinical features, developmental abilities and
- 363 social-emotional-behavioural characteristics. We suggest that the group-wise distributions of ID
- 364 severity, neuroanatomical features and ophthalmological abnormalities are expanding with broader
- 365 ascertainment of individuals with CASK variants. The relationships between structural brain
- 366 development, epilepsy and developmental trajectories warrant further investigation in this group.

# 367 Abbreviations

- 368 **AAC:** Augmentative and Alternative Communication
- 369 ASD: Autism Spectrum Disorder
- 370 **B-H FDR:** Benjamini-Hochberg False Discovery Rate
- 371 BINGO: Brain and Behaviour in Neurodevelopmental disorder of Genetic Origin
- 372 CASK: Calcium/calmodium-dependent serine protein kinase
- 373 CNV: Copy Number Variant
- 374 CYP: Children and Young People
- 375 CVI: Cerebral Visual Impairment
- 376 DBC2: Developmental Behaviour Checklist, Second Edition
- 377 FCVIQ: Flemish Cerebral Visual Impairment Questionnaire
- 378 ID: Intellectual Disability

It is made available under a CC-BY 4.0 International license .

- 379 MAGUK: Membrane-associated Guanylate Kinase
- 380 MHQ: Medical History Questionnaire
- 381 MICPCH: Microcephaly and pontine cerebellar hypoplasia
- 382 MRI: Magnetic Resonance Imaging
- 383 NGS: Next Generation Sequencing
- 384 **PECS:** Picture Exchange Communication System
- 385 *RBQ:* Repetitive Behaviour Questionnaire
- 386 SNV: Single Nucleotide Variant
- 387 SRS-2: Social Responsiveness Scale, Second Edition
- 388 VABS: Vineland Adaptive Behaviour Scale
- 389 XLID: X-linked Intellectual Disability

# 390 **Declarations**

#### 391 Availability of data and materials

- 392 Anonymised data may be made available to other researchers from the corresponding author on
- reasonable request, and on condition of signing a Code of Conduct guaranteeing that the data will
- be kept confidential and securely.
- 395 Ethics declarations
- 396 Ethics approval and consent to participate
- 397 Study protocol was approved by the Cambridge Central Research Ethics Committee (IRAS reference:
- 398 11/EE/0330, 'Phenotypes in Intellectual Disability'), and written informed consent was obtained
- from each participant's parent/caregiver prior to inclusion.

It is made available under a CC-BY 4.0 International license .

### 400 Consent for publication

- 401 Not applicable
- 402 Competing interests
- 403 The authors declare no competing interests.

#### 404 Acknowledgements

- 405 We thank all of the children and young people with CASK-related disorder and their families for their
- 406 participation in the BINGO project. We thank the charities who supported our research and
- 407 recruitment of participants into the BINGO project, in particular CASK Research Foundation, Angelina
- 408 CASK Neurological Research Foundation, Association Enfants CASK France, Unique, Cambridge Rare
- 409 Disease Network, and Genetic Alliance UK.

### 410 Funding

- 411 This study was funded by the Medical Research Council (MC\_UU\_00030/3), Great Ormond Street
- 412 Hospital Charity, and Cambridge NIHR Biomedical Research Centre.
- 413 Author Information
- 414 Authors and Affiliations
- 415 MRC Cognition and Brain Sciences Unit, University of Cambridge, 15 Chaucer Road, Cambridge,
- 416 Cambridgeshire CB2 7EF
- 417 Jessica Martin, Alkistis Mavrogalou-Foti, Josefine Eck, Kate Baker
- 418 CASK Research Foundation, 33 Finchdean Road, Rowlands Castle, Hampshire PO9 6DA
- 419 Laura Hattersley
- 420 Department of Medical Genetics, University of Cambridge, Addenbrooke's Treatment Centre,
- 421 Cambridge Biomedical Campus, Cambridge, Cambridgeshire CB2 0QQ
- 422 Kate Baker

It is made available under a CC-BY 4.0 International license .

- 423 Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, Cambridgeshire
- 424 CB2 1QP
- 425 Kate Baker
- 426 Contributions
- 427 JM and KB designed and conceptualised the study, with assistance of LH. JM led data collection,
- 428 supported by AMF and JE. Data analysis and the literature review were conducted by JM and AMF.
- 429 JM wrote the first draft of the manuscript. AMF wrote parts of the manuscript. KB provided
- 430 supervision, and reviewed and edited the manuscript. All authors read and approved the final
- 431 manuscript.

434

## 432 References

433 1. Pan YE, Tibbe D, Harms FL, Reißner C, Becker K, Dingmann B, et al. Missense mutations in *CASK*,

coding for the calcium-/calmodulin-dependent serine protein kinase, interfere with neurexin

- binding and neurexin-induced oligomerization. J Neurochem. 2021 May;157(4):1331–50.
- 436 2. Froyen G, Van Esch H, Bauters M, Hollanders K, Frints SGM, Vermeesch JR, et al. Detection of
- 437 genomic copy number changes in patients with idiopathic mental retardation by high-resolution
- 438 X-array-CGH: important role for increased gene dosage of *XLMR* genes. Hum Mutat. 2007
- 439 Oct;28(10):1034–42.
- Hayashi S, Mizuno S, Migita O, Okuyama T, Makita Y, Hata A, et al. The CASK gene harbored in a
  deletion detected by array-CGH as a potential candidate for a gene causative of X-linked
- dominant mental retardation. Am J Med Genet A. 2008 Aug 15;146A(16):2145–51.
- 443 4. Hayashi S, Okamoto N, Chinen Y, Takanashi J ichi, Makita Y, Hata A, et al. Novel intragenic
- 444 duplications and mutations of CASK in patients with mental retardation and microcephaly with
- 445 pontine and cerebellar hypoplasia (MICPCH). Hum Genet. 2012 Jan;131(1):99–110.

It is made available under a CC-	BY 4.0 International license .
----------------------------------	--------------------------------

446	5	Havashi S	Llehara DT	Tanimoto K	Mizuno S	Chinen Y	Fukumura S	et al	Comprehensive
440	J.	110 y 0 3 111 3,		ι ταπιποτό κ,	IVIIZUIIO J,	CHILLER I	, i ukumuta J	, ci ai.	comprenensive

- 447 investigation of CASK mutations and other genetic etiologies in 41 patients with intellectual
- disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH). Bardoni B, editor.
- 449 PLOS ONE. 2017 Aug 7;12(8):e0181791.
- 450 6. Najm J, Horn D, Wimplinger I, Golden JA, Chizhikov VV, Sudi J, et al. Mutations of CASK cause an
- X-linked brain malformation phenotype with microcephaly and hypoplasia of the brainstem and
  cerebellum. Nat Genet. 2008 Sep;40(9):1065–7.
- 453 7. Hackett A, Tarpey PS, Licata A, Cox J, Whibley A, Boyle J, et al. CASK mutations are frequent in
- 454 males and cause X-linked nystagmus and variable XLMR phenotypes. Eur J Hum Genet. 2010
  455 May;18(5):544–52.
- Tarpey PS, Smith R, Pleasance E, Whibley A, Edkins S, Hardy C, et al. A systematic, large-scale
   resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet. 2009
   May;41(5):535–43.
- 9. Dimitratos SD, Stathakis DG, Nelson CA, Woods DF, Bryant PJ. The Location of HumanCASKat
  Xp11.4 Identifies This Gene as a Candidate for X-Linked Optic Atrophy. Genomics. 1998
  Jul;51(2):308–9.
- 462 10. Dunn P, Prigatano GP, Szelinger S, Roth J, Siniard AL, Claasen AM, et al. A de novo splice site
  463 mutation in *CASK* causes FG syndrome-4 and congenital nystagmus. Am J Med Genet A. 2017
  464 Mar;173(3):611–7.
- 465 11. Piluso G, D'Amico F, Saccone V, Bismuto E, Rotundo IL, Di Domenico M, et al. A Missense
  466 Mutation in CASK Causes FG Syndrome in an Italian Family. Am J Hum Genet. 2009
- 467 Feb;84(2):162–77.

- 468 12. Moog U, Kutsche K. CASK Disorders. In: GeneReviews<sup>®</sup> [Internet] [Internet]. Seattle (WA):
- 469 University of Washington, Seattle; 2020. Available from:
- 470 https://www.ncbi.nlm.nih.gov/books/NBK169825/
- 471 13. Becker M, Mastropasqua F, Reising JP, Maier S, Ho ML, Rabkina I, et al. Presynaptic dysfunction
- in CASK-related neurodevelopmental disorders. Transl Psychiatry. 2020 Sep 14;10(1):312.
- 473 14. Dubbs H, Ortiz-Gonzalez X, Marsh ED. Pathogenic variants in CASKID: Expanding the genotype-
- 474 phenotype correlations. Am J Med Genet A. 2022 Sep;188(9):2617–26.
- 475 15. Moog U, Bierhals T, Brand K, Bautsch J, Biskup S, Brune T, et al. Phenotypic and molecular
- insights into CASK-related disorders in males. Orphanet J Rare Dis. 2015 Dec;10(1):44.
- 477 16. Seto T, Hamazaki T, Nishigaki S, Kudo S, Shintaku H, Ondo Y, et al. A novel CASK mutation
- identified in siblings exhibiting developmental disorders with/without microcephaly. Intractable
- 479 Rare Dis Res. 2017;6(3):177–82.
- 480 17. LaConte LEW, Chavan V, Elias AF, Hudson C, Schwanke C, Styren K, et al. Two microcephaly-
- 481 associated novel missense mutations in CASK specifically disrupt the CASK–neurexin interaction.
- 482 Hum Genet. 2018 Mar;137(3):231–46.
- 483 18. LaConte LEW, Chavan V, DeLuca S, Rubin K, Malc J, Berry S, et al. An N-terminal heterozygous
- 484 missense CASK mutation is associated with microcephaly and bilateral retinal dystrophy plus
  485 optic nerve atrophy. Am J Med Genet A. 2019 Jan;179(1):94–103.
- 486 19. Burglen L, Chantot-Bastaraud S, Garel C, Milh M, Touraine R, Zanni G, et al. Spectrum of
- 487 pontocerebellar hypoplasia in 13 girls and boys with CASK mutations: confirmation of a
- 488 recognizable phenotype and first description of a male mosaic patient. Orphanet J Rare Dis.
- 489 2012;7(1):18.

It is made available under a CC-BY 4.0 International license .

- 490 20. Moog U, Kutsche K, Kortum F, Chilian B, Bierhals T, Apeshiotis N, et al. Phenotypic spectrum
- 491 associated with CASK loss-of-function mutations. J Med Genet. 2011 Nov 1;48(11):741–51.
- 492 21. Giacomini T, Nuovo S, Zanni G, Mancardi MM, Cusmai R, Pepi C, et al. CASK related disorder:
- 493 Epilepsy and developmental outcome. Eur J Paediatr Neurol. 2021 Mar;31:61–9.
- 494 22. Mori T, Zhou M, Tabuchi K. Diverse Clinical Phenotypes of CASK-Related Disorders and Multiple

495 Functional Domains of CASK Protein. Genes. 2023 Aug 20;14(8):1656.

- 496 23. Lindsay N, Runicles A, Johnson MH, Jones EJH, Bolton PF, Charman T, et al. Early development
- 497 and epilepsy in tuberous sclerosis complex: A prospective longitudinal study. Dev Med Child
- 498 Neurol. 2024 May;66(5):635–43.
- 499 24. Tye C, Mcewen FS, Liang H, Underwood L, Woodhouse E, Barker ED, et al. Long-term cognitive

500 outcomes in tuberous sclerosis complex. Dev Med Child Neurol. 2020 Mar;62(3):322–9.

- 501 25. Bar C, Breuillard D, Kuchenbuch M, Jennesson M, Le Guyader G, Isnard H, et al. Adaptive
- 502 behavior and psychiatric comorbidities in KCNB1 encephalopathy. Epilepsy Behav. 2022
  503 Jan;126:108471.
- 26. Levy T, Gluckman J, Siper PM, Halpern D, Zweifach J, Filip-Dhima R, et al. Clinical, genetic, and
  cognitive correlates of seizure occurrences in Phelan-McDermid syndrome. J Neurodev Disord.
  2024 May 10;16(1):25.
- Takanashi J, Okamoto N, Yamamoto Y, Hayashi S, Arai H, Takahashi Y, et al. Clinical and
  radiological features of Japanese patients with a severe phenotype due to *CASK* mutations. Am J
  Med Genet A. 2012 Dec;158A(12):3112–8.

- 510 28. Valayannopoulos V, Michot C, Rodriguez D, Hubert L, Saillour Y, Labrune P, et al. Mutations of
- 511 TSEN and CASK genes are prevalent in pontocerebellar hypoplasias type 2 and 4. Brain. 2012 Jan
- 512 1;135(1):e199–e199.
- 513 29. Sparrow SS, Cicchetti DV, Saulnier, CA. Vineland adaptive behavior scales: Third edition
- 514 (Vineland-3). Bloomington: NCS Pearson.; 2016.
- 515 30. Ortibus E, Laenen A, Verhoeven J, De Cock P, Casteels I, Schoolmeesters B, et al. Screening for
- 516 Cerebral Visual Impairment: Value of a CVI Questionnaire. Neuropediatrics. 2011

517 Aug;42(04):138–47.

- 518 31. Constantino JN, Gruber CP. Social Responsiveness Scale–Second Edition (SRS-2). Torrance, CA:
- 519 Western Psychological Services.; 2012.
- 520 32. Einfeld SL, Tonge BJ. The Developmental Behavior Checklist: The development and validation of
- 521 an instrument to assess behavioral and emotional disturbance in children and adolescents with
- 522 mental retardation. J Autism Dev Disord. 1995 Apr;25(2):81–104.
- 523 33. Moss J, Oliver C. The Repetitive Behaviour Scale. Manual for administration and scorer
- 524 interpretation. Birmingham, UK: University of Birmingham.; 2008.
- 34. Lee NR, Niu X, Zhang F, Clasen LS, Kozel BA, Smith ACM, et al. Variegation of autism related traits
   across seven neurogenetic disorders. Transl Psychiatry. 2022 Apr 7;12(1):149.
- 527 35. Lubbers K, Stijl EM, Dierckx B, Hagenaar DA, Ten Hoopen LW, Legerstee JS, et al. Autism
- 528 Symptoms in Children and Young Adults With Fragile X Syndrome, Angelman Syndrome,
- 529 Tuberous Sclerosis Complex, and Neurofibromatosis Type 1: A Cross-Syndrome Comparison.
- 530 Front Psychiatry. 2022 May 16;13:852208.

It is made available under a CC-BY 4.0 International license .

- 531 36. Hyman P, Oliver C, Hall S. Self-injurious behavior, self-restraint, and compulsive behaviors in
- 532 Cornelia de Lange syndrome. Am J Ment Retard. 2002;107(2):146–54.
- 533 37. Arron K, Oliver C, Moss J, Berg K, Burbidge C. The prevalence and phenomenology of self-
- 534 injurious and aggressive behaviour in genetic syndromes: Self-injurious behaviour in genetic
- 535 syndromes. J Intellect Disabil Res. 2011 Feb;55(2):109–20.
- 536 38. Eden KE, de Vries PJ, Moss J. Self-injury and aggression in tuberous sclerosis complex: cross
- 537 syndrome comparison and associated risk markers. J Neurodev Disord [Internet]. 2014;6(10).
- 538 Available from: https://doi.org/10.1186/1866-1955-6-10
- 539 39. Bissell S, Oliver C, Moss J, Heald M, Waite J, Crawford H, et al. The behavioural phenotype of
- 540 SATB2-associated syndrome: a within-group and cross-syndrome analysis. J Neurodev Disord.
  541 2022 Dec;14(1):25.
- 542 40. Dunn W, Little LM, Dean E, Robertson S, Evans B. The Sensory Profile 2: Short Sensory Profile.
  543 2nd ed. Pearson; 2014.
- 544 41. Agar G, Brown C, Sutherland D, Coulborn S, Oliver C, Richards C. Sleep disorders in rare genetic

545 syndromes: a meta-analysis of prevalence and profile. Mol Autism. 2021;12(1):1–17.

- 546 42. Surtees ADR, Oliver C, Jones CA, Evans DL, Richards C. Sleep duration and sleep quality in people
  547 with and without intellectual disability: A meta-analysis. Sleep Med Rev. 2018 Aug;40:135–50.
- 548 43. Tietze AL, Blankenburg M, Hechler T, Michel E, Koh M, Schlüter B, et al. Sleep disturbances in
  549 children with multiple disabilities. Sleep Med Rev. 2012 Apr;16(2):117–27.
- 550 44. Pearson EV, Waite J, Oliver C. Differences in the Information Needs of Parents With a Child With

a Genetic Syndrome: A Cross-Syndrome Comparison. J Policy Pract Intellect Disabil.

552 2018;15(2):94–100.

- 553 45. Trickett J, Heald M, Oliver C. Sleep in children with Angelman syndrome: Parental concerns and
- priorities. Res Dev Disabil. 2017 Oct;69:105–15.
- 555 46. Cohen S, Fulcher BD, Rajaratnam SMW, Conduit R, Sullivan JP, Hilaire MAS, et al. Behaviorally-
- 556 determined sleep phenotypes are robustly associated with adaptive functioning in individuals
- with low functioning autism. Sci Rep. 2017 Oct 27;7(1):14228.
- 558 47. Brooks LJ, Olsen MN, Bacevice AM, Beebe A, Konstantinopoulou S, Taylor HG. Relationship
- between sleep, sleep apnea, and neuropsychological function in children with Down syndrome.
- 560 Sleep Breath. 2015 Mar;19(1):197–204.
- 48. Rzepecka H, McKenzie K, McClure I, Murphy S. Sleep, anxiety and challenging behaviour in
  children with intellectual disability and/or autism spectrum disorder. Res Dev Disabil. 2011
  Nov;32(6):2758–66.
- 49. Cohen S, Fulcher BD, Rajaratnam SMW, Conduit R, Sullivan JP, St Hilaire MA, et al. Sleep patterns
  predictive of daytime challenging behavior in individuals with low-functioning autism. Autism
  Res. 2018 Feb;11(2):391–403.
- 567 50. Coleman H, Mannion A, Whelan S, Tones M, Heussler H, Bellgard M, et al. Association Between
- 568 Challenging Behaviour and Sleep Problems in Adults Enrolled in the Global Angelman Syndrome
- 569 Registry. J Autism Dev Disord [Internet]. 2024 May 20 [cited 2024 Sep 18]; Available from:
- 570 https://link.springer.com/10.1007/s10803-024-06367-6
- 571 51. John A, Ng-Cordell E, Hanna N, Brkic D, Baker K. The neurodevelopmental spectrum of synaptic
  572 vesicle cycling disorders. J Neurochem. 2021;157(2):208–28.
- 573 52. Shaw E, Flitcroft I, Bowman R, Baker K. Cerebral visual impairment: genetic diagnoses and
- 574 phenotypic associations. J Med Genet. 2024 Jun;61(6):605–12.

It is made available under a CC-BY 4.0 International license .

- 575 53. Besag FMC, Vasey MJ. Neurocognitive Effects of Antiseizure Medications in Children and
- 576 Adolescents with Epilepsy. Pediatr Drugs. 2021 May;23(3):253–86.
- 577 54. Strzelczyk A, Schubert-Bast S. Psychobehavioural and Cognitive Adverse Events of Anti-Seizure
- 578 Medications for the Treatment of Developmental and Epileptic Encephalopathies. CNS Drugs.
- 579 2022 Oct;36(10):1079–111.
- 580 55. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of
- 581 the epilepsies: Position paper of the ILAE Commission for Classification and Terminology.
- 582 Epilepsia. 2017 Apr;58(4):512–21.
- 583 56. Ben Itzhak N, Vancleef K, Franki I, Laenen A, Wagemans J, Ortibus E. Visuoperceptual profiles of
- 584 children using the Flemish cerebral visual impairment questionnaire. Dev Med Child Neurol.
- 585 2020 Aug;62(8):969–76.
- 586 57. Crotti M, Ortibus E, Mailleux L, Decraene L, Kleeren L, Itzhak NB. Visual, perceptual functions,
- 587 and functional vision in children with unilateral cerebral palsy compared to children with
- 588 neurotypical development. Dev Med Child Neurol. 2024 Aug;66(8):1084–95.

It is made available under a CC-BY 4.0 International license .

# 590 Figure legends

- 591 Figure 1. Vineland Adaptive Behaviour Scales age standardised scores within the BINGO CASK-
- related disorder group. Legend: ID severity cut-offs are overlaid in red and annotated in black for the
- 593 VABS composite score. Mean scores on each measure are represented by the black diamond.
- 594 Figure 2. Social Responsiveness Scale T-scores within the BINGO CASK-related disorder group.
- 595 Legend: Severity cut-offs are overlaid in red and annotated in black for the SRS-2 total score. Mean
- scores on each measure are represented by the black diamond.
- 597 Figure 3. Developmental Behaviour Checklist T-scores within the BINGO CASK-related disorder
- 598 group. . Legend: Levels of concern are overlaid in red and annotated in black for all DBC2 measures.
- 599 Mean scores on each measure are represented by the black diamond.
- 600 **Figure 4.** Restricted and repetitive Behaviour Questionnaire Scores within the BINGO CASK-related
- disorder group. Legend: Severity cut-offs are overlaid in red and annotated in black for all RBQ

602 measures. Mean scores on each measure are represented by the black diamond.

- 603 Figure 5. Flemish cerebral visual impairment questionnaire Factors scores within the BINGO CASK-
- related disorder group. Legend: Mean scores for children with CVI (taken from 32) are overlaid in
- red, and mean scores for children with CVI and unilateral (taken from 33) are overlaid in blue. Mean
- scores on each measure for the BINGO CASK-related group are represented by the black diamond.
- Figure 6. Correlations between demographic and neurodevelopmental domains within *CASK*-relateddisorder.

It is made available under a CC-BY 4.0 International license .

### 610 **Table 1.** Comparison between reviewed cases and BINGO *CASK*-related disorder group.

Characteristics (Total; n (%))	<b>Reviewed</b> Cases	BINGO Participants
Sample details		
Sample size	151	31
Females	109 (72.2)	27 (87.1)
Age: range (mean) / months <sup>a</sup>	0.5-588	36-310 (118.8)
Genetic details		
SNV	108/151 (71.5)	20/27 (74.1)
Truncating	47/108 (43.5)	13/20 (65.0)
Missense	38/108 (35.2)	2/20 (10.0)
Intronic	22/108 (20.4)	5/20 (25.0)
CNV	43/151 (28.5)	7/27 (25.9)
Intragenic	28/43 (65.1)	6/7 (85.7)
Multi-gene	14/43 (32.6)	1/7 (14.3)
Uncertain	1/43 (2.3)	0/7 (0.0)
Inheritance		
De novo	68/88 (77.3)	12/15 (80.0)
Inherited	20/88 (22.7)	3/15 (20.0)
Feeding difficulties	56/98 (57.1)	26/31 (83.9)
Tone abnormalities		
Hypotonia	64/112 (57.1)	13/31 (41.9)
Hypertonia	38/91 (41.8)	6/31 (19.4)
Mixed	8/57(14.0)	7/31 (22.6)
OA		
Optic atrophy	32/112 (28.6)	3/31 (9.7)
Strabismus	34/112 (30.4)	8/31 (25.8)
Nystagmus	28/112 (25)	1/31 (3.2)
Other	30/78 (38.5)	18/31 (58.1)
SNHL	28/114 (24.6)	7/31 (22.6)
Seizures	66/135 (48.9)	11/31 (35.5)
<i>DD/</i> ID <sup>b</sup>		
Mild/moderate	13/108 (12.0)	17/28 (60.7)
Severe	81/108 (75.0)	7/28 (25.0)
Profound	14/108 (13.0)	4/28 (14.3)
Developmental milestones		
Able to sit	64/113 (56.6)	27/31 (87.1)
Age acquired / months	6-36	7-36
Able to walk	26/101 (25.7)	16/31 (51.6)
Age acquired / months	18-72	13-108
Verbal abilities	23/68 (33.8)	14/31 (45.2)
Brain abnormalities <sup>c</sup>		
MICPCH	121/139 (87.1)	11/25 (44.0)
CH and/or PH only	5/139 (3.6)	1/25 (4.0)
MIC and other	4/139 (2.9)	1/25 (4.0)
MIC and CH	3/139 (2.1)	1/25 (4.0)
MIC only	3/139 (2.1)	8/25 (32.0)
Other abnormalities only	0/139 (0.0)	1/25 (4.0)
No abnormalities	3/139 (2.1)	2/25 (8.0)

It is made available under a CC-BY 4.0 International license .

- 611 Notes:
- 612 Absolute frequencies of clinical information are reported with the denominator indicating the
- 613 number of individuals for whom information was available.
- <sup>a</sup> The mean age of individuals in previous papers was not possible to calculate.
- 615 <sup>b</sup> DD/ID was reported in previous papers using medical reports. In current study, VABS composite
- 616 categorised as 'mild/moderate', 'severe' and 'profound' to align with previously reported
- 617 classifications was used as a proxy measure of severity of DD/ID.
- 618 <sup>c</sup> In previous papers, we reported cases where MRI reports were available. In current study,
- 619 information about microcephaly and structural brain abnormalities were obtained via MRI, genetic
- 620 and parental reports.
- 621 Abbreviations:
- 622 CH: cerebellar hypoplasia; CNV: copy number variant; DD/ID: developmental delay or intellectual
- disability; MIC: microcephaly; MICPCH: microcephaly with pontine and cerebellar hypoplasia; OA:
- 624 Ophthalmological Abnormalities; PH: pontine hypoplasia; SNHL: sensorineural hearing loss; SNV:
- 625 single nucleotide variant.





SRS-2 Measure







**CVI** Factor

